SYK

SYK

USD

Stryker Corporation Common Stock

$356.030+1.400 (0.395%)

リアルタイム価格

Healthcare
医療機器
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$354.630

高値

$357.500

安値

$352.500

出来高

1.68M

企業ファンダメンタルズ

時価総額

136.2B

業種

医療機器

United States

取引統計

平均出来高

1.39M

取引所

NYQ

通貨

USD

52週レンジ

安値 $329.16現在値 $356.030高値 $406.19

AI分析レポート

最終更新: 2025年11月2日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

After a Steep Plunge, Is Stryker (SYK) Poised for a Comeback?

Generated: November 02, 2025, 11:15 AM EDT

Wall Street's Verdict: Analysts Stand Firm Despite the Turmoil

Even as Stryker's stock price took a beating, the mood among market analysts remains surprisingly upbeat. The latest reports show a strong consensus. Barclays, for instance, recently boosted its price target to an ambitious $453, maintaining an "Overweight" rating. BTIG followed suit, nudging its target up to $410 with a solid "Buy."

There was one minor note of caution. Evercore ISI trimmed its target slightly, from $410 to $405. However, they kept their "Outperform" rating, signaling continued confidence in the company's direction. This pattern of unwavering support from analysts, even in the face of a sharp sell-off, suggests they believe the recent drop is a temporary setback, not a fundamental flaw in the business. News of the company showcasing its new trauma portfolio also adds a positive, forward-looking element to the narrative.

The Anatomy of a Sell-Off: Charting Stryker's Rocky Quarter

The last three months have been a wild ride for Stryker shareholders. The stock climbed steadily through August, peaking above $394 in early September. Then, the momentum shifted. A slow, grinding decline began, pulling the price down through the rest of the month.

Things took a dramatic turn on the final day of October. The stock plunged sharply, closing at $356.24. This wasn't a quiet drift downward; it was a stampede for the exits. Trading volume exploded to more than double its daily average, indicating a major event or a wave of panic selling. This kind of move often washes out weak hands, but it also leaves investors wondering what comes next. The stock went from a high near $395 to a low near $355 in just two months--a significant reversal that has reset the board.

The Digital Crystal Ball: AI Signals a Strong Bounce-Back

While the recent price chart looks grim, predictive algorithms are telling a completely different story. The AI forecast points to a swift and powerful rebound in the immediate future.

AI Price Forecast (Next 3 Days)

DayPredicted Change
1+1.27%
2+2.90%
3+4.29%

This forecast is backed by high confidence from the model. It seems to view the recent plunge as a classic overreaction, creating a strong buying opportunity. This optimism is fueled by the positive news sentiment and strong analyst ratings. However, the picture isn't entirely rosy. The system also flags some conflicting technical signals, like a bearish MACD crossover, and points out the company's high debt-to-equity ratio. It's a classic battle: the bearish reality of the recent price drop versus the bullish promise of a data-driven forecast.

The Bottom Line

The data for Stryker Corporation presents a fascinating contradiction. On one hand, you have a brutal, high-volume sell-off that has shaken investor confidence. On the other, you have firm conviction from Wall Street analysts and a highly confident AI model predicting a significant short-term recovery.

For a medium-term investor who can stomach some volatility, the current situation could present an opportunity. The AI model suggests the selling is overdone. A strategy based on this data would involve entering a position near the recent lows, anticipating a bounce toward the AI's target of $376.39.

A cautious approach is warranted. The provided data suggests potential entry points between $371.16 and $373.38. To manage risk, a stop-loss at $332.11 would be prudent to protect against a continued slide. If the AI's predicted bounce materializes, taking profits around the $376.39 level would align with the model's short-term outlook. The conflicting technical and fundamental signals--especially the high debt--should not be ignored and add a layer of risk to this potential trade.


Disclaimer: This report is for informational purposes only and does not constitute financial advice, an offer to sell, or a solicitation of an offer to buy any security. The analysis is based solely on the structured data provided and may not reflect all market conditions or future events. Investing in stocks involves risk, including the possible loss of principal. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

関連ニュース

Analyst Upgrades

Truist Securities Reiterates Hold on Stryker, Lowers Price Target to $392

Truist Securities analyst Richard Newitter reiterates Stryker with a Hold and lowers the price target from $407 to $392.

もっと見る
Truist Securities Reiterates Hold on Stryker, Lowers Price Target to $392
Analyst Upgrades

Evercore ISI Group Maintains Outperform on Stryker, Lowers Price Target to $405

Evercore ISI Group analyst Vijay Kumar maintains Stryker with a Outperform and lowers the price target from $410 to $405.

もっと見る
Evercore ISI Group Maintains Outperform on Stryker, Lowers Price Target to $405
Analyst Upgrades

BTIG Maintains Buy on Stryker, Raises Price Target to $410

BTIG analyst Ryan Zimmerman maintains Stryker with a Buy and raises the price target from $408 to $410.

もっと見る
BTIG Maintains Buy on Stryker, Raises Price Target to $410
Analyst Upgrades

Barclays Maintains Overweight on Stryker, Raises Price Target to $453

Barclays analyst Matt Miksic maintains Stryker with a Overweight and raises the price target from $443 to $453.

もっと見る
Barclays Maintains Overweight on Stryker, Raises Price Target to $453
BusinessWire

Stryker to Feature Expanding Trauma Portfolio at the Orthopaedic Trauma Association Annual Meeting 2025

Stryker (NYSE:SYK), a global leader in medical technologies, will showcase new additions to its trauma offerings at the Orthopaedic Trauma Association (OTA) Annual Meeting, October 15–18, in Phoenix, Ariz. (booth #601).

もっと見る
Stryker to Feature Expanding Trauma Portfolio at the Orthopaedic Trauma Association Annual Meeting 2025

AI予測Beta

AI推奨

強気

更新日時: 2025年11月10日 08:51

弱気中立強気

70.0% 信頼度

リスクと取引

リスクレベル3/5
中リスク
適しているのは
保守的
取引ガイド

エントリーポイント

$356.64

利確

$374.33

損切り

$320.40

主要因子

PDI 6.6はMDI 5.9の上にあり、ADX 11.0とともに強気トレンドを示唆しています
現在の価格はサポートレベル(355.67ドル)に非常に接近しており、強力な買い機会を示唆しています
出来高は平均(14,928)の10.5倍で、極めて強い買い圧力を示しています
MACD -0.1054はシグナルライン-0.0445の下にあり、弱気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。